Qlife announces that it has closed a license and supply agreement with Aidian Oy to access and incorporate their patented SIBA® Technology into the Egoo.Health platform.
Corona virus, COVID-19, has limited impact on Qlife Holding AB
Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak. The interest for our Egoo Home System has not waned. On the contrary, the interest in being able to test patients at home compared to at a hospital is increasingly attractive in a time where limitation of infection is in focus. This is a focus that will have even more attention in the future when our health sector needs to be prepared if or when a similar situation evolves.
This increasing interest makes up for the short-term effects of the corona virus where Qlife are following the guidelines of the Danish government to limit the spread and to protect their employees from infection. All non-essential international travels have been cancelled and all employees, for whom its possible, are from today, March 13th working from home.
“We believe that the potential for the Egoo Home System is increasing in the long run, and we prepare ourselves for deliveries to a healthcare system that will have been under a lot of pressure and will need all the technological aid they can to bounce back stronger than before” Thomas Warthoe, CEO
Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak.
Qlife Holding AB announces that the trading in the company’s shares (short name: QLIFE) will commence today on the Nasdaq First North Growth Market in Stockholm.
The short name for the Company’s shares on Nasdaq First North is QLIFE. The short name for the TO1 series warrants is QLIFE TO1.
The Egoo Home System is an integrated platform consisting of a small device, disposable capsules, each a test for a specific biomarker, and a digital infrastructure that can share data with patient
CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Stockholm on 25 November.
CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Gothenburg on 4 November and in Stockholm on 25 November.
The home diagnostic device from Danish start-up Qlife can make the lives of patients with chronic diseases easier.
Qlife is showcased by the Danish Minister of Health and the Minister for Industry, Business and Financial Affairs for the launch of new public program for innovative purchasing of medical equipment